![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Publication history |
Reprints |
Permissions |
Cite this article as |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
Minerva Endocrinology 2021 Mar 16
DOI: 10.23736/S2724-6507.21.03289-2
Copyright © 2021 EDIZIONI MINERVA MEDICA
language: English
Metformin improves survival in patients with concurrent diabetes and small cell lung cancer: a meta-analysis
Hua FAN 1, Shikun BAI 2, Xin GUAN 1, Wen MA 1, Yu FU 1, Xuan ZHANG 1, Lili DENG 3, Jing TIAN 1 ✉
1 Department of Oncology and Hematology, People’s Hospital of Leshan,Leshan City, P.R China; 2 Emergency Medicine Department, People’s Hospital of Leshan, Leshan City, P.R China; 3 Ultrasound Imaging Department, People’s Hospital of Leshan, Leshan City, P.R China
OBJECTIVE: To compare survival outcome among the patients with concurrent small cell lung cancer (SCLC) and diabetes mellitus (DM) using metformin or without metformin.
METHODS: A systematic literature search for relevant studies up to Oct 2020 was conducted. Outcome of the included studies included overall survival (OS) or disease-free survival (DFS). HR values were pooled to estimate the effect of metformin on survival outcomes.
RESULTS: 6 studies with 539 participants with both SCLC and diabetes were included in the analysis. The patients with metformin usage had significantly longer OS and DFS than those without metformin usage [OS: HR=0.72 (0.53-0.98), p=0.04; DFS: HR= 0.59 (0.45-0.76), p<0.0001)]. The studies included were not significantly different in the two analyses by heterogeneity test. There was no obvious publication bias.
CONCLUSIONS: Metformin may improve survival among patients with concurrent SCLC and DM. Further investigations especially randomized control trials are warranted, especially among the patients who do not have diabetes.
KEY WORDS: Small cell lung cancer; Diabetes; Metformin; Survival